Assessing Glycemic Control in Diabetic Patients With Severe Nephropathy

Journal of Renal Nutrition

Volumn 23, Issue 3, 2013, Pages 199-202

  Robinson, Todd W ^a   Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SERUM ALBUMIN;

CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; HYPERGLYCEMIA; KIDNEY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; UNITED STATES;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; SERUM ALBUMIN; UNITED STATES;

EID: 84876729822     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.01.021     Document Type: Review

References (21)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(suppl 1):S62-S69.
2. Zoungas S., de Galan B.E., Ninomiya T., et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009, 32:2068-2074.
3. Ismail-Beigi F., Craven T., Banerji M.A., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010, 376:419-430.
4. Freedman B.I. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease. Diabetes Care 2012, 35:1621-1624.
5. Kalantar-Zadeh K. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Diabetes Care 2012, 35:1625-1628.
6. Williams M.E., Lacson E., Teng M., Ofsthun N., Lazarus J.M. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006, 70:1503-1509.
7. Williams M.E., Lacson E., Wang W., Lazarus J.M., Hakim R. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 2010, 5:1595-1601.
8. Williams M.E., Lacson E., Teng M., Hakim R.M., Lazarus J.M. Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. Am J Nephrol 2009, 29:54-61.
9. Kalantar-Zadeh K., Kopple J.D., Regidor D.L., et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007, 30:1049-1055.
10. Ricks J., Molnar M.Z., Kovesdy C.P., et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes 2012, 61:708-715.
11. Duong U., Mehrotra R., Molnar M.Z., et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011, 6:1041-1048.
12. Hoshino J., Molnar M.Z., Yamagata K., et al. Developing an HbA1c-based equation to estimate blood glucose in maintenance hemodialysis patients. Diabetes Care 2012, Available at:. http://www.ncbi.nlm.nih.gov/pubmed/23238664.
13. Kohzuma T., Yamamoto T., Uematsu Y., Shihabi Z.K., Freedman B.I. Basic performance of an enzymatic method for glycated albumin and reference range determination. J Diabetes Sci Technol 2011, 5:1455-1462.
14. Koga M., Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010, 57:751-762.
15. Armbruster D.A. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987, 33:2153-2163.
16. Inaba M., Okuno S., Kumeda Y., et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007, 18:896-903.
17. Peacock T.P., Shihabi Z.K., Bleyer A.J., et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008, 73:1062-1068.
18. Freedman B.I., Andries L., Shihabi Z.K., et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011, 6:1635-1643.
19. Murea M., Moran T., Russell G.B., et al. Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis. Am J Nephrol 2012, 36:488-496.
20. Freedman B.I., Shihabi Z.K., Andries L., et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 2010, 31:375-379.
21. Selvin E., Steffes M.W., Ballantyne C.M., Hoogeveen R.C., Coresh J., Brancati F.L. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011, 154:303-309.